🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT06802965
Enrolling by invitation Observational

Shanghai Atrial Fibrillation Registry

NCT06802965 · tracked via the Priya Life Science China tracker
Sponsor
Xinhua Hospital, Shanghai Jiao Tong University School of Medicine
Phase
Observational
Started
2025-01-01
Last updated
2025-01-31

Condition(s) studied

Atrial Fibrillation (AF)

Investigational drug(s) / intervention(s)

catheter ablation, left atrial appendage closure

catheter ablation, left atrial appendage closure: Compare the clinical prognosis of patients with AF underwent the combined procedure of catheter ablation and left atrial appendage closure (LAAC), single catheter ablation and single LAAC.

Study summary

Using the Shanghai Municipal Health Commission database and Shanghai Centers for Disease Control and Prevention database, patients with AF in Shanghai are included to construct the Shanghai AF registry to investigate clinical characteristics, treatment, and prognosis.

Eligibility

Sex
ALL
Min age
—
Max age
—
Healthy volunteers
No
Inclusion Criteria: * With diagnosis of AF: the diagnosis must be identified from the Shanghai Municipal Health Commission database and verified by 12-lead ECG or Holter monitoring since 2015 * Residents of Shanghai * Taking part in the government-issued health insurance, including the Urban Residents' Basic Medical Insurance (URBMI), the Urban-Employ Based Medical Insurance (UEBMI) and the New Rural Cooperative Medical Scheme (NRCMS). Exclusion Criteria: * Non-residence of Shanghai * Without the government-issued health insurance * Die at the day of index diagnosis of AF

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Xinhua Hospital, School of Medicine, Shanghai Jiao Tong University Shanghai China

More Xinhua Hospital, Shanghai Jiao Tong University School of Medicine trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT06802965 on ClinicalTrials.gov ↗ ← All trials in China